AstraZeneca reports positive results from endometrial cancer therapy trial

AstraZeneca has reported positive high-level results from the DUO-E trial (GOG 3041/ENGOT-EN10) of Imfinzi (durvalumab) and platinum-based chemotherapy combination followed by Imfinzi with Lynparza (olaparib) or Imfinzi alone as maintenance therapy in advanced or recurrent endometrial cancer patients.